Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis

Clinical trial NCT06216392 · UNKNOWN

Trial details

NCT number: NCT06216392
Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Atopic Dermatitis

Start date: 2024-01-01
Primary completion: 2025-06-01
Enrollment: 450

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.